481 related articles for article (PubMed ID: 30633615)
21. Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study.
Guo J; Zhang H; Zhang H; Lai X; Wang J; Feng H; Fang H
Vaccine; 2023 Jan; 41(3):716-723. PubMed ID: 36522264
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia.
Ordóñez JE; Orozco JJ
BMC Infect Dis; 2014 Mar; 14():172. PubMed ID: 24679135
[TBL] [Abstract][Full Text] [Related]
24. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.
Wu DB; Roberts C; Lee VW; Hong LW; Tan KK; Mak V; Lee KK
Hum Vaccin Immunother; 2016; 12(2):403-16. PubMed ID: 26451658
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of pneumococcal vaccines for adults in the United States.
Chen J; O'Brien MA; Yang HK; Grabenstein JD; Dasbach EJ
Adv Ther; 2014 Apr; 31(4):392-409. PubMed ID: 24718851
[TBL] [Abstract][Full Text] [Related]
27. The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England.
Danelian G; Burton L; Bayley T; Sanchez-Marroquin A; Park J; Manley H; Choi Y; Andrews N; Ladhani S; Earnshaw A; Gritzfeld JF; Trotter C; Panovska-Griffiths J
Vaccine; 2024 Jul; 42(18):3838-3850. PubMed ID: 38763851
[TBL] [Abstract][Full Text] [Related]
28. A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult.
Ngamprasertchai T; Kositamongkol C; Lawpoolsri S; Rattanaumpawan P; Luvira V; Chongtrakool P; Kaewkungwal J; Chokephaibulkit K; Phisalprapa P
Front Public Health; 2023; 11():1071117. PubMed ID: 37457251
[TBL] [Abstract][Full Text] [Related]
29. Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium.
Willem L; Blommaert A; Hanquet G; Thiry N; Bilcke J; Theeten H; Verhaegen J; Goossens H; Beutels P
Hum Vaccin Immunother; 2018 May; 14(5):1218-1229. PubMed ID: 29420161
[TBL] [Abstract][Full Text] [Related]
30. Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany.
Kuchenbecker U; Chase D; Reichert A; Schiffner-Rohe J; Atwood M
PLoS One; 2018; 13(5):e0197905. PubMed ID: 29795647
[TBL] [Abstract][Full Text] [Related]
31. Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.
Castiglia P; Pradelli L; Castagna S; Freguglia V; Palù G; Esposito S
Hum Vaccin Immunother; 2017 Oct; 13(10):2307-2315. PubMed ID: 28700264
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
Jiang Y; Gauthier A; Keeping S; Carroll S
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):913-27. PubMed ID: 25189087
[TBL] [Abstract][Full Text] [Related]
33. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context?
Kulpeng W; Leelahavarong P; Rattanavipapong W; Sornsrivichai V; Baggett HC; Meeyai A; Punpanich W; Teerawattananon Y
Vaccine; 2013 Jun; 31(26):2839-47. PubMed ID: 23588084
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults.
Smith KJ; Nowalk MP; Raymund M; Zimmerman RK
Vaccine; 2013 Aug; 31(37):3950-6. PubMed ID: 23806240
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China.
Zhao D; Gai Tobe R; Cui M; He J; Wu B
Vaccine; 2016 Dec; 34(50):6158-6165. PubMed ID: 27838068
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness Comparison of Pneumococcal Conjugate Vaccines in Turkish Children.
Marijam A; Olbrecht J; Ozakay A; Eken V; Meszaros K
Value Health Reg Issues; 2019 Sep; 19():34-44. PubMed ID: 30776766
[TBL] [Abstract][Full Text] [Related]
37. Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single-dose vaccination strategy for adults in Hong Kong.
Shami JJP; Pathadka S; Chan EW; Hui J; Sato R; Patil S; Li X
Hum Vaccin Immunother; 2020 Aug; 16(8):1937-1944. PubMed ID: 31977268
[TBL] [Abstract][Full Text] [Related]
38. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
Hoshi SL; Kondo M; Okubo I
PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.
Mo X; Gai Tobe R; Liu X; Mori R
Pediatr Infect Dis J; 2016 Nov; 35(11):e353-e361. PubMed ID: 27753771
[TBL] [Abstract][Full Text] [Related]
40. Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions.
Treskova M; Scholz SM; Kuhlmann A
Pharmacoeconomics; 2019 Sep; 37(9):1093-1127. PubMed ID: 31025189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]